Cerevel Therapeutics Holdings, Inc. (CERE)
- GlobeNewswire
Cerevel Therapeutics to Present at the Stifel 2023 CNS Days
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will participate in a fireside chat at the Stifel Virtual 2023 CNS Days on Wednesday, March 29, 2023 at 10:30 am ET. The live webcast of the presentation can be accessed on the investor relations section of the Cerevel Therapeutics websi
- GlobeNewswire
Cerevel Therapeutics to Present at the 43rd Annual Cowen Health Care Conference
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 43rd Annual Cowen Health Care Conference. Date: Monday, March 6, 2023 Format: Presentation at 9:10 a.m. EST The live webcast of the presentation can be accessed on the investor relations section of the Cereve
- GlobeNewswire
Cerevel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Emraclidine Phase 1 healthy elderly volunteer trial enrollment underway to support development in Alzheimer’s disease psychosis Emraclidine Phase 2 schizophrenia data readout remains on track for 1H 2024 Clinical trial timeline updates provided for additional lead programs Cash, cash equivalents, and marketable securities of $950 million as of December 31, 2022, expected to support operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cere
